Preclinical antitumor activity of CI-994

Investigational New Drugs

Volumn 14, Issue 4, 1996, Pages 349-356

  LoRusso, Patricia Mucci ^a   Demchik, Lisa ^a   Foster, Brenda ^d   Knight, Juiwanna ^a   Bissery, Marie Christine ^b   Polin, Lisa Marie ^d   Leopold III, Wilbur R ^c   Corbett, Thomas H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b SANOFI   (France)

^c PFIZER INC   (United States)

^d NONE

Author keywords

Acetyldinaline; CI 994; Preclinical antitumor activity

Indexed keywords

4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DINALINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOSARCOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOLID TUMOR;

EID: 0030469421     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00180810     Document Type: Article

References (26)

1. Berger MR, Richter H, Seelig MH, Eibl H, Schmahl D: New cytostatics: more activity and less toxicity. Cancer Treat Rev 17:143-154, 1990
2. Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool BL, Satzinger G, Schmahl D, Weiershausen U: Synthesis, toxicity and therapeutic efficacy of 4-amino-N-(2′-aminophenyl) benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 69:1415-1424, 1985
3. Lelieveld P, Middeldorp RJF, Van Putten LM: Effectiveness of P-aminobenzoyl-O-phenylenediamine (GOE 1734) against mouse, rat and human tumor cells. Cancer Chemother Pharmacol 15:88-90, 1985
4. Berger MR, Schmahl D: Antineoplastic activity of two 4-amino-N-(2′-aminophenyl)benzamide (GOE 1734) derivatives in rat mammary carcinoma. Proc Am Assoc Cancer Res 28:301, 1987
5. Berger MR, Richter H, Seelig MH, Eibl H, Schmahl D: New cytostatics: more activity and less toxicity. Cancer Treat Rev 17:143-154, 1990
6. Kraker AJ, Moore CW: Activity and effects of 4-amino-N-(2-aminophenyl)benzamide (GOE 1734, PD 104208): a compound with a novel mechanism of action, against HCT-8. Proc Am Assoc Cancer Res 30:584, 1991
7. Leopold WR, Hook KE, Fry DW: Activity of biochemical properties of GOE 1734 (PD 104208), an anticancer agent with a novel mechanism of activity. Proc Am Assoc Cancer Res 28:302, 1988
8. Hagenbeek A, Weiershausen U, Martens ACM: Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML). Leukemia (Baltimore) 2:226-230, 1988
9. Howard C, Roberts B, Vincent P, Elliott W: N-acetyl-dinaline: a small molecule with in vivo cytostatic activity. Proc Am Assoc Cancer Res 33:393, 1992
10. Rummel SA, Kraker AJ, Steinkampf RW, Hook KE, Klohs WD: Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int J Cancer 62:636-642, 1995
11. Rummel S, Steinkampf R, Auerbach R, Kraker A, Klohs W: Specific loss of a 16 kD phosphoprotein in colon tumor cells treated with the novel antitumor compound CI-994 [4-(acetylamino)-N-(2-aminophenyl)benzamide, N-acetyldinine]. Proc Am Assoc Cancer Res 34:369, 1993
12. Klohs W, Kraker A, Steinkampf R, Moore C, Dominick M: Mitochondrial involvement in the mechanism of action of the novel antitumor compound 4-(acetylamino)-N(2-aminophenyl)benzamide (PD-123654, GOE 5549). Proc Am Assoc Cancer Res 32:396, 1991
13. Kraker AJ, Wolven A, Fry DW, Klohs WD: Cell cycle and nucleotide metabolism effects of 4-(acetylamino)-N-(2-aminophenyl) benzamide (PD 123654, GOE 5549) in HCT-8 cells. Proc Am Assoc Cancer Res 32:396, 1991
14. Rummel SA, Steinkampf RW, Kraker AJ, Klohs WD: The role of protein phosphorylation in the mechanism of 4-(acetylamino)-N-(2-aminophenyl) benzamide (N-Acetyldinaline, CI-994). Proc Am Assoc Cancer Res 33:514, 1992
15. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of pancreas in C57B1/6 mice. Cancer Res 44:717-726, 1984
16. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35:2434-2439, 1975
17. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr: Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42:1701-1715, 1982
18. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660-2680, 1977
19. Corbett TH, Roberts BJ, Trader MW Jr, Laster WR Jr, Griswold DP Jr, Schabel FM Jr: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5):1187-1200, 1982
20. Hiramoto RN, Ghanta VK: Surgical adjuvant chemotherapy of metastatic murine osteosarcoraa. Int J Cancer 25:393-397, 1980
21. Corbett TH, Valeriote FA, Polin L et al.: Discovery of solid tumor active agents using a soft-agar-colony-formation-disk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (eds), Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp 35-87. Norwell, Massachusetts: Kluwer Academic Publishers, 1992
22. LoRusso PM, Polin L, Biernat LA, Valeriote FA, Corbett TH: Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Invest New Drugs 8:253-261, 1990
23. Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: Kallman RF (ed), The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, pp 233-247. Elmsford, NY: Pergamon Press, 1987
24. Graziano M, Walsh K: Two-week oral toxicity study of CI-994 in rats. Proc Am Assoc Cancer Res 35:460, 1994
25. Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50(4):219-244
26. LoRusso P, Wozniak A, Foster B, Parchment R, Volpe D, Meyer M, Radulovic L, Corbett TH, Valdivieso M: Phase I trial of extended daily dosing of acetyldinaline (CI-994) (abstract). Submitted NCI-EORTC, November 1995